112758-88-0

Usage

Molecular structure

1-benzyl-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine (BZTP) has a unique molecular structure that belongs to the class of heterocyclic compounds.

Antifungal

It can inhibit the growth of fungi.

Antibacterial

It has the ability to combat bacterial infections.

Antitumor

BZTP shows potential in preventing the growth of cancer cells.

Central nervous system depressant

BZTP has demonstrated potential as a central nervous system depressant, which can help in calming the nervous system and reducing anxiety.

Therapeutic applications

Due to its versatile properties, BZTP is a target for drug development in the treatment of anxiety and related disorders.

Field of study

BZTP is commonly used in medicinal chemistry and pharmaceutical research, making it an interesting target for further exploration and study in the field.

Upstream product

• 100-44-7 benzyl chloride 
• 71257-37-9 3,4-dihydropyrrolo[1,2-a]-pyrazine 
• 103-80-0 phenylacetyl chloride 
• 29709-35-1 1-(2-aminoethyl)pyrrole 
• 71257-38-0 1,2,3,4-Tetrahydropyrrolo<1,2-a>pyrazine 
• 111609-52-0 1-Benzyl-3,4-dihydropyrrolo<1,2-a>pyrazine 

Relevant academic research and scientific papers

A Robust, Recyclable Resin for Decagram Scale Resolution of (±)-Mefloquine and Other Chiral N-Heterocycles

Decagram quantities of enantiopure (+)-mefloquine have been produced via kinetic resolution of racemic mefloquine using a ROMP-gel supported chiral acyl hydroxamic acid resolving agent. The requisite monomer was prepared in a few synthetic steps without chromatography and polymerization was safely performed on a >30 gram scale under ambient conditions. The reagent was readily regenerated and reused multiple times for the resolution of 150 grams of (±)-mefloquine and other chiral N-heterocylces.

Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain

Substituted tetrahydropyrrolopyrazine compounds corresponding to the formula I: processes for their preparation, pharmaceutical compositions comprising these compounds and the use of these compounds for the treatment and/or inhibition of pain and other disorders or disease states at least partly mediated by KCNQ2/3 K+ channels.